Actively Recruiting

Age: 0Years - 89Years
All Genders
NCT05915208

Histiocytic Disorder Follow-up Study

Led by University of Alabama at Birmingham · Updated on 2025-06-11

6000

Participants Needed

1

Research Sites

326 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders

CONDITIONS

Official Title

Histiocytic Disorder Follow-up Study

Who Can Participate

Age: 0Years - 89Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of any histiocytic disorder at any age
  • Includes Langerhans cell histiocytosis
  • Includes Erdheim-Chester disease
  • Includes Rosai-Dorfman disease
  • Includes Xanthogranuloma
  • Includes mixed histiocytosis
  • Includes malignant histiocytosis such as histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma
  • Includes hemophagocytic lymphohistiocytosis
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

Actively Recruiting

Loading map...

Research Team

G

Gaurav Goyal, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here